Fig. 3: Titers and expression of the engineered AAV vectors. | Nature Communications

Fig. 3: Titers and expression of the engineered AAV vectors.

From: The therapeutic implications of all-in-one AAV-delivered epigenome-editing platform in neurodegenerative disorders

Fig. 3

The titers of the a dCjCas9 and b dSaCas9-vectors. Lane 1: negative. Lane 2: HP1a-no-hinge/no-gRNA. Lane 3: HP1a-no-hinge/gRNA1. Lane 4: HP1a-no-hinge/gRNA2. Lane 5: HP1a-hinge/no-gRNA. Lane 6: HP1a-hinge/gRNA1. Lane 7: HP1a-hinge/gRNA2. Lane 8: HP1b/no-gRNA. Lane 9: HP1b-no-hinge-gRNA1. Lane 10: HP1b-no-hingle-gRNA2. Lane 11: HP1b-hinge/no-gRNA. Lane 12: HP1b-hinge/gRNA1. Lane 13: HP1b-hinge/gRNA2. Lane 14: MBD1/no-gRNA. Lane 15: MBD1/gRNA1. Lane 16: MBD1/gRNA2. Lane 17: MBD2/no-gRNA. Lane 17: MBD2/gRNA1. Lane 18: MBD2/gRNA2. Lane 19: MBD3/no-gRNA. Lane 20: MBD3/gRNA1. Lane 21: MBD3/gRNA2. Lane 22: NIPP1/no-gRNA. Lane 23: NIPP1/gRNA1. Lane 24: NIPP1/gRNA2. Lane 25: KRAB/no-gRNA. Lane 26: KRAB/gRNA1. Lane 27: KRAB/gRNA2. Lane 28: MeCP2/no-gRNA. Lane 29: MeCP2/gRNA1. Lane 30: MeCP2/gRNA2. Lane 31: KRAB-MeCP2/no-gRNA. Lane 32: KRAB-MeCP2/gRNA1. Lane 33: KRAB-MeCP2/gRNA2. Lane 34: DNMT3A/no-gRNA. Lane 35: DNMT3A/gRNA1. Lane 36: DNMT3A/gRNA2. Lane 37: DNMT3B/no-gRNA. Lane 38: DNMT3B/gRNA1. Lane 39: DNMT3B/gRNA2. b the lane order is the same as for dCjCas9 in (a). The statistical analysis was done using Prism GraphPad. Ordinary one-way ANOVA was carried out to determine significant difference in the samples’ means ± SEM. ns P > 0.05, *P ≤ 0.05, **P ≤ 0.01. ***P ≤ 0.001, ****P ≤ 0.0001; multiple comparisons of means were determined using Tukey’s test. Expression of the vectors: dCjCas9 (c) and dSaCas9 (d). The lane’s order is the same as for (a, b). Relative light units (RLU) were recorded. The statistical analysis, as above (c P < 0.0001, d P < 0.0001).

Back to article page